News coverage of midlife symptoms reinforces careful testosterone assessment and highlights why fertility matters before treatment decisions.
On October 22, 2026, The Citizen published Salome Gregory’s report “Breaking silence on men’s midlife hormonal changes” from Dar es Salaam. Clinician Dr Julius Twoli advised medical assessment for persistent symptoms rather than assuming they are caused by aging.
This article is for informational purposes only and is not medical advice. Personal decisions about testing or treatment belong with a qualified clinician.
In The Citizen’s report, the changes discussed covered sexual health as well as energy and physical function. The symptoms listed included:
The practical distinction is between noticing a change and deciding what caused it. Dr Twoli’s advice was to have persistent symptoms assessed. It was not to use the list as a shortcut to testosterone treatment.
The report also used the term andropause for gradual testosterone decline that may accompany physical, sexual or emotional changes. For a reader, that term provides a topic for discussion rather than a personal diagnosis.
Psychologist Cosmas Maduhu told The Citizen that expectations for men to remain strong and emotionally resilient may discourage some from discussing changes or seeking professional help. He recommended medical and psychological support for persistent changes in mood, sleep, energy or sexual health.
That advice concerns the barrier to seeking care, not a claim that symptoms are a sign of weakness. A medical conversation can begin with a clear description of the concern rather than a confident explanation of its cause.
The psychological point also broadens the conversation beyond a testosterone number. Maduhu’s comments covered mood and sleep alongside energy and sexual health. Those are appropriate concerns to describe in their own terms, rather than leaving them out because they do not fit a preferred explanation. His recommendation was professional support for persistent changes, with medical and psychological care both part of the discussion.
The European Association of Urology’s male hypogonadism guidance gives the clinical framework behind this advice. Diagnosis rests on compatible signs and symptoms together with low morning testosterone on at least two occasions. It specifies a reliable assay and fasting conditions.
An assay is the laboratory method used to measure testosterone. The guidance therefore links the person’s symptoms with biochemical evidence obtained under defined conditions. A symptom checklist and a laboratory report answer different parts of that assessment.
The main elements have separate roles:
Reading the standard as a whole matters. Testing is not presented as a replacement for a discussion of symptoms, and symptoms are not presented as a replacement for testing. The combination is the basis for assessing hypogonadism, the medical condition addressed by the guidance.
In an appointment, it helps to distinguish the reason for seeking care from the evidence used to evaluate it. A change in sexual desire or ongoing fatigue is a reason to raise a concern. The diagnostic assessment then connects that concern to the signs and repeated measurements specified by the guidance. This preserves the difference between taking a symptom seriously and assigning it a hormonal cause.
For a reader, the useful question is how the symptoms and measurements fit together. That is different from choosing whichever result or symptom seems most persuasive. Testostra’s explanation of how clinicians interpret repeat testosterone results provides related context.
Dr Twoli also cautioned in The Citizen that testosterone therapy can reduce sperm production and affect fertility. The European Association of Urology guidance explains the mechanism: exogenous testosterone inhibits gonadotropin secretion. Exogenous means testosterone supplied from outside the body.
That inhibition can impair sperm production and maturation. This is a reproductive effect, not simply another description of fatigue or a change in sexual desire. It makes fertility a separate part of a treatment discussion.
The guidance describes testosterone therapy as contraindicated for men with hypogonadism seeking fertility treatment. In this context, contraindicated means the guidance advises against using the treatment for that group.
That warning creates an important distinction between recognizing possible hormone symptoms and deciding whether a particular treatment fits someone’s circumstances. Reproductive goals belong in that conversation before a therapy decision, rather than being treated as a detail to address afterward.
Questions about sexual desire, erections and having children also need clear wording. They are not interchangeable treatment goals. Testostra’s discussion of bringing sexual symptoms and fertility concerns into an assessment offers related context.
The Citizen story is a local news report built around clinician and psychologist interviews plus one man’s experience. It is not a clinical study, a prevalence survey or a new guideline. Its contribution is to bring attention to assessment and fertility, rather than to establish a new diagnostic rule.
The article includes a 45-year-old man’s account of tiring more easily, sometimes sleeping poorly and noticing changes in sexual desire. That experience gives the subject a human perspective. It does not establish how common those changes are among men of the same age.
Variation also limits how age-related language should be read. The report says patterns and effects differ between men. Not every man develops symptoms or significant health problems, and Dr Twoli said low testosterone is not inevitable with aging.
The Citizen quoted Dr Julius Twoli as saying testosterone typically declines by about 1% annually from around ages 30 to 40. That figure is a clinician’s statement reported by the newspaper, not a population estimate independently established by the accompanying urology guidance. It should not be treated as a universal timetable for a man’s hormone levels or symptoms.
The interviews do not establish how much any symptom would improve with treatment. Diagnostic guidance describes how a condition is assessed; it is not a prediction of an individual treatment response.
Dr Twoli’s recommendation was to bring persistent concerns to medical assessment. For readers, the practical next step is a conversation with a qualified clinician rather than treating a news story as a prescription. The issues raised in the report can help organize that conversation:
These are discussion points, not a testing protocol or a treatment recommendation. They keep the focus on clinical interpretation while leaving personal decisions to qualified care. For more context, see Testostra’s explanation of assessing symptoms alongside hormone results.
Bottom line: this report should not immediately change current medical practice. It reinforces established guidance on connecting symptoms with repeated low morning measurements and on considering fertility before treatment. Its immediate value is a clearer reason to seek assessment, not a new reason to start testosterone therapy.
A midlife symptom list becomes misleading when it is treated as a diagnosis. Testostra addresses uncertainty about those changes with evidence-led reporting on testosterone and male hormonal health, helping readers prepare clearer questions about possible causes. Its educational coverage keeps emerging findings distinct from established guidance without directing personal diagnosis or hormone treatment.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra